Zh.Zh. Zholdybay ¹, Zh.K. Zhakenova ¹, A.S. Ainakulova ^1,2, М.О. Gabdullina ¹, J.M. Amankulov ², Е.V. Filippenko ¹, B.K. Isamatov ¹, A.S. Alakova ¹, Yu.T. Dautova ¹

1. «Asfendiyarov Kazakh National Medical University» NCJSC, Almaty, the Republic of Kazakhstan;
2. «Kazakh Institute of Oncology and Radiology» JSC, Almaty, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2663-4864-2023-3-69-65-71

UDC: 616-006-073.756.8

Year: 2023 issure: 69 number: 3 pages: 65-71

Download PDF:

ABSTRACT

Relevance: The incidence of malignant neoplasms of various localizations is growing worldwide and in Kazakhstan. The mortality rate from oncological diseases is also alarmingly high. To facilitate early diagnosis and optimal therapy, scientists are exploring molecular diagnostics, including PET/CT, using various markers, like ¹⁸F-fluorodeoxyglucose, widely used in oncology but lacking specificity for certain types of tumors. The finding of Fibroblast Activation Protein (FAP) has sparked interest in FAP-targeted radiolabeled inhibitors (FAPI), which could serve as a universal marker for diagnosing different types of cancer. Various FAP markers for PET/CT are being studied, with special attention given to ⁶⁸Ga-FAPI.
The study aimed to analyze the potential value of FAPI PET/CT for detecting malignant tumors.
Methods: A literature review was conducted using the MEDLINE, Embase, Scopus, PubMed, and Cochrane Central Register of Controlled Trials databases for the past decade using the following keywords: “malignant lesions,” “PET/CT,” and “FAPI.” This review analyzes 48 literature sources with A1-level evidence dedicated to the ⁶⁸Ga-FAPI PET/CT diagnostic accuracy in detecting and staging malignant tumors and assessing treatment efficacy.
Results: According to the analyzed sources, the 68Ga-FAPI PET/CT sensitivity and specificity in diagnosing cancer is 95% to 100% and 62% to 100%, respectively. However, clear indications for use in clinical practice require further study of 68Ga-FAPI PET/CT diagnostic capabilities on larger cohorts and more homogeneous datasets.
Conclusion: The available literature data on FAPI PET/CT diagnostic capacity shows this marker’s potential in diagnosing oncological disorders. Information provided by ⁶⁸Ga-FAPI PET/CT supplements the existing nuclear medicine methods and generally impacts the treatment strategy for each unique case.
Keywords: malignant lesions, PET/CT, FAPI.

List of sources used:

1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries // CA Cancer J Clin. – 2021. – Vol. 71, №3. – P. 209-249. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660
2. Кайдарова Д.Р., Балтабеков Н.Т., Душимова З.Д., Шатковская О.В. и др. Показатели онкологической службы Республики Казахстан за 2020 год: статистические и аналитические материалы – Алматы, 2021. – 226 с. [Kajdarova D.R., Baltabekov N.T., Dushimova Z.D., Shatkovskaya O.V. i dr. Pokazateli onkologicheskoj sluzhby Respubliki Kazaxstan za 2020 god: statisticheskie i analiticheskie materialy / – Almaty, 2021. – 226 s. (in Russ., Kaz., En.)] https://onco.kz/news/pokazateli-onkologicheskoj-sluzhby-respubliki-kazahstan-za-2020-god/
3. Rowe S.P., Pomper M.G. Molecular imaging in oncology: Current impact and future directions // CA Cancer J Clin. – 2022. – Vol. 72, №4. – P. 333-352. https://doi.org/10.3322/caac.21713
4. James M.L., Gambhir S.S. A molecular imaging primer: modalities, imaging agents, and applications // Physiol Rev. – 2012. – Vol. 92, №2. – P. 897-965. https://doi.org/10.1152/physrev.00049.2010
5. Alavi A., Reivich M. Guest editorial: the conception of FDG-PET imaging // Semin Nucl Med. – 2002. – Vol. 32, №1. – P. 2-5. https://doi.org/10.1053/snuc.2002.29269.
6. Gomes Marin J.F., Nunes R.F., Coutinho A.M., Zaniboni E.C., Costa L.B., Barbosa F.G., Queiroz M.A., Cerri G.G., Buchpiguel C.A. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology // Radiographics. – 2020. – Vol. 6(40). – P. 1715-1740. https://doi.org/10.1148/rg.2020200021
7. Garin-Chesa P., Old L.J., Rettig W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers // Proc Natl Acad Sci USA. – 1990. – Vol. 87, №18. – P. 7235-7239. https://doi.org/10.1073/pnas.87.18.7235
8. Calais J. FAP: The Next Billion Dollar Nuclear Theranostics Target? // J Nucl Med. – 2020. – Vol. 61, №2. – P. 163-165. https://doi.org/10.2967/jnumed.119.241232
9. Liu F., Qi L., Liu B., Liu J., Zhang H., Che D., Cao J., Shen J., Geng J., Bi Y., Ye L., Pan B., Yu Y. // PLoS One. – 2015. – Vol. 16, №10(3) – P. 88-101. https://doi.org/10.1371/journal.pone.0116683
10. Dendl K., Koerber S.A., Kratochwil C., Cardinale J., Finck R., Dabir M., Novruzov E., Watabe T., Kramer V., Choyke P.L., Haberkorn U., Giesel F.L. FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis Perfect Symbiosis? // Cancers (Basel). – 2021. – Vol. 13, №19. – P. 44-49. https://doi.org/10.3390/cancers13194946
11. Loktev A., Lindner T., Mier W., Debus J., Altmann A., Jäger D., Giesel F., Kratochwil C., Barthe P., Roumestand C., Haberkorn U. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts // J Nucl Med. – 2018. – Vol. 59, №9. – P. 1423-1429. https://doi.org/10.2967/jnumed.118.210435
12. Kratochwil C., Flechsig P., Lindner T., Abderrahim L., Altmann A., Mier W., Adeberg S., Rathke H., Röhrich M., Winter H., Plinkert P.K., Marme F., Lang M., Kauczor H.U., Jäger D., Debus J., Haberkorn U., Giesel F.L. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer // J Nucl Med. – 2019. – Vol. 60, №6. – P. 801-805. https://doi.org/10.2967/jnumed.119.227967
13. Zhao L., Pang Y., Zheng H., Han C., Gu J., Sun L., Wu H., Wu S., Lin Q., Chen H. Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma // Eur J Nucl Med Mol Imaging. – 2021. – Vol. 48, №11. – P. 3606-3617. https://doi.org/10.1007/s00259-021-05336-w
14. Linz C., Brands R.C., Kertels O., Dierks A., Brumberg J., Gerhard-Hartmann E., Hartmann S., Schirbel A., Serfling S., Zhi Y., Buck A.K., Kübler A., Hohm J., Lapa C., Kircher M. Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [18F]FDG PET/CT and MRI // Eur J Nucl Med Mol Imaging. – 2021. – Vol. 48, №12. – P. 3951-3960. https://doi.org/10.1007/s00259-021-05422-z
15. Serfling S., Zhi Y., Schirbel A., Lindner T., Meyer T., Gerhard-Hartmann E., Lapa C., Hagen R., Hackenberg S., Buck A.K., Scherzad A. Improved cancer detection in Waldeyer’s tonsillar ring by 68Ga-FAPI PET/CT imaging // Eur J Nucl Med Mol Imaging. – 2021. – Vol. 48, №4. – P. 1178-1187. https://doi.org/10.1007/s00259-020-05055-8
16. Windisch P., Röhrich M., Regnery S., Tonndorf-Martini E., Held T., Lang K., Bernhardt D., Rieken S., Giesel F., Haberkorn U., Debus J., Adeberg S. Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma // Radiother Oncol. – 2020. – Vol. 150. – P. 159-163. https://doi.org/10.1016/j.radonc.2020.06.040
17. Röhrich M., Loktev A., Wefers A.K., Altmann A., Paech D., Adeberg S., Windisch P., Hielscher T., Flechsig P., Floca R., Leitz D., Schuster J.P., Huber P.E., Debus J., von Deimling A., Lindner T., Haberkorn U. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT // Eur J Nucl Med Mol Imaging. – 2019. – Vol. 46, №12. – P. 2569-2580. https://doi.org/10.1007/s00259-019-04444-y
18. Wen S., Qu N., Ma B., Wang X., Luo Y., Xu W., Jiang H., Zhang Y., Wang Y., Ji Q. Cancer-Associated Fibroblasts Positively Correlate with Dedifferentiation and Aggressiveness of Thyroid Cancer // Onco Targets Ther. – 2021. – Vol. 22;14. – P. 1205-1217. https://doi.org/10.2147/OTT.S294725
19. Fu H., Fu J., Huang J., Su X., Chen H. 68Ga-FAPI PET/CT in Thyroid Cancer with Thyroglobulin Elevation and Negative Iodine Scintigraphy // Clin Nucl Med. – 2021. – Vol. 1, №46(5). – P. 427-430. https://doi.org/10.1097/RLU.0000000000003569
20. Fu H., Fu J., Huang J., Pang Y., Chen H. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer // Clin Nucl Med. – 2021. – Vol. 1, №46(11). – P. 940-942. https://doi.org/10.1097/RLU.0000000000003730
21. Aleskandarany M.A., Vandenberghe M.E., Marchiò C., Ellis I.O., Sapino A., Rakha E.A.. Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine // Pathobiology. – 2018. – Vol. 85, №1-2. – P. 23-34. https://doi.org/10.1159/000477851.
22. Dendl K., Koerber S.A., Finck R., Mokoala K.M.G., Staudinger F., Schillings L., Heger U., Röhrich M., Kratochwil C., Sathekge M., Jäger D., Debus J., Haberkorn U., Giesel F.L. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies // Eur J Nucl Med Mol Imaging. – 2021. – Vol. 48, №12. – P. 4089-4100. https://doi.org/10.1007/s00259-021-05378-0
23. Kömek H., Can C., Güzel Y., Oruç Z., Gündoğan C., Yildirim Ö.A., Kaplan İ., Erdur E., Yıldırım M.S., Çakabay B. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT // Ann Nucl Med. – 2021. – Vol. 35, №6. – P. 744-752. https://doi.org/10.1007/s12149-021-01616-5
24. Elboga U., Sahin E., Kus T., Cayirli Y.B., Aktas G., Uzun E., Cinkir H.Y., Teker F., Sever O.N., Aytekin A., Yilmaz L., Aytekin A., Cimen U., Mumcu V., Kilbas B., Çelen Y.Z. Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer // Ann Nucl Med. – 2021. – Vol. 35, №12. – P. 1321-1331. https://doi.org/10.1007/s12149-021-01672-x
25. Kuyumcu S., Has-Simsek D., Iliaz R., Sanli Y., Buyukkaya F., Akyuz F., Turkmen C. Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT // Clin Nucl Med. – 2019. – Vol. 44, №9. – P. 702-706. https://doi.org/10.1097/RLU.0000000000002701
26. Shi X., Xing H., Yang X., Li F., Yao S., Zhang H., Zhao H., Hacker M., Huo L., Li X. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules // Eur J Nucl Med Mol Imaging. – 2021. – Vol. 48, №1. – P. 196-203. https://doi.org/10.1007/s00259-020-04882-z
27. Shi X., Xing H., Yang X., Li F., Yao S., Congwei J., Zhao H., Hacker M., Huo L., Li X. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study // Eur J Nucl Med Mol Imaging. – 2021. – Vol. 48, №5. – P. 1593-1603. https://doi.org/10.1007/s00259-020-05070-9
28. Röhrich M., Naumann P., Giesel F.L., Choyke P.L., Staudinger F., Wefers A., Liew D.P., Kratochwil C., Rathke H., Liermann J., Herfarth K., Jäger D., Debus J., Haberkorn U., Lang M., Koerber S.A. Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas // J Nucl Med. – 2021. – Vol. 1, №62(6). – P. 779-786. https://doi.org/10.2967/jnumed.120.253062
29. Pang Y., Huang H., Fu L., Zhao L., Chen H. 68Ga-FAPI PET/CT Detects Gastric Signet-Ring Cell Carcinoma in a Patient Previously Treated for Prostate Cancer // Clin Nucl Med. – 2020. – Vol. 45, №8. – P. 632-635. https://doi.org/10.1097/RLU.0000000000003099
30. Lin R., Lin Z., Zhang J., Yao S., Miao W. Increased 68Ga-FAPI-04 Uptake in Schmorl Node in a Patient With Gastric Cancer // Clin Nucl Med. – 2021. – Vol. 1, №46(8). – P. 700-702. https://doi.org/10.1097/RLU.0000000000003623
31. Qin C., Shao F., Gai Y., Liu Q., Ruan W., Liu F., Hu F., Lan X. 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT // J Nucl Med. – 2022. – Vol. 63, №1. – P. 81-88. https://doi.org/10.2967/jnumed.120.258467
32. Pang Y., Zhao L., Luo Z., Hao B., Wu H., Lin Q., Sun L., Chen H. Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers // Radiology. – 2021. – Vol. 298, №2. – P. 393-402. https://doi.org/10.1148/radiol.2020203275
33. Lin R., Lin Z., Chen Z., Zheng S., Zhang J., Zang J., Miao W. [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT // Eur J Nucl Med Mol Imaging. – 2022. – Vol. 49, №8. – P. 2960-2971. https://doi.org/10.1007/s00259-022-05799-5
34. Koerber S.A., Staudinger F., Kratochwil C., Adeberg S., Haefner M.F., Ungerechts G., Rathke H., Winter E., Lindner T., Syed M., Bhatti I.A., Herfarth K., Choyke P.L., Jaeger D., Haberkorn U., Debus J., Giesel F.L. The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience // J Nucl Med. – 2020. – Vol. 61, №9. – P. 1331-1336. https://doi.org/10.2967/jnumed.119.237016
35. Zhao L., Pang Y., Luo Z., Fu K., Yang T., Zhao L., Sun L., Wu H., Lin Q., Chen H. Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT // Eur J Nucl Med Mol Imaging. – 2021. – Vol. 48, №6. – P. 1944-1955. https://doi.org/10.1007/s00259-020-05146-6
36. Schmidkonz C., Rauber S., Atzinger A., Agarwal R., Götz T.I., Soare A., Cordes M., Prante O., Bergmann C., Kleyer A., Ritt P., Maschauer S., Hennig P., Toms J., Köhner M., Manger B., Stone J.H., Haberkorn U., Baeuerle T., Distler J.H.W., Agaimy A., Kuwert T., Schett G., Ramming A. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging // Ann Rheum Dis. – 2020. – Vol. 79, №11. – P. 1485-1491. https://doi.org/10.1136/annrheumdis-2020-217408
37. Sandberg T.P., Stuart M.P.M.E., Oosting J., Tollenaar R.A.E.M., Sier C.F.M., Mesker W.E. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer // BMC Cancer. – 2019. – Vol. 29, №19(1). – P. 163-165. https://doi.org/10.1186/s12885-019-5462-2.
38. Prashanth A., Kumar Ravichander S., Eswaran P., Kalyan S., Maheswari Babu S. Diagnostic performance of Ga-68 FAPI 04 PET/CT in colorectal malignancies // Nucl Med Commun. – 2023. – Vol. 1;44(4). – P. 276-283. https://doi.org/10.1097/MNM.0000000000001661
39. Elboga U., Sahin E., Kus T., Cayirli Y.B., Aktas G., Okuyan M.., Cinkir H.Y, Teker F., Sever O.N., Aytekin A., Yılmaz L., Aytekin A., Cimen U., Mumcu V., Kilbas B., Eryilmaz K., Cakici D., Celen Y.Z. Comparison of 68Ga-FAPI PET/CT and 18FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement // Mol Imaging Biol. – 2022. – Vol. 24, №5. – P. 789-797. https://doi.org/10.1007/s11307-022-01729-x
40. Syed M., Flechsig P., Liermann J., Windisch P., Staudinger F., Akbaba S., Koerber S.A., Freudlsperger C., Plinkert P.K., Debus J., Giesel F., Haberkorn U., Adeberg S. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers // Eur J Nucl Med Mol Imaging. – 2020. – Vol. 47, №12. – P. 2836-2845. https://doi.org/10.1007/s00259-020-04859-y
41. Röhrich M., Syed M., Liew D.P., Giesel F.L., Liermann J., Choyke P.L., Wefers A.K., Ritz T., Szymbara M., Schillings L, Heger U., Rathke H., Kratochwil C., Huber P.E., von Deimling A., Debus J., Kauczor H.U., Haberkorn U., Adeberg S. 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation // Radiother Oncol. – 2021. – Vol. 160. – P. 192-201. https://doi.org/10.1016/j.radonc.2021.04.016
42. Lai D., Ma L., Wang F. Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells // Int J Oncol. – 2012. – Vol. 41, №2. – P. 541-50. https://doi.org/10.3892/ijo.2012.1475
43. Hussain A., Voisin V., Poon S., Karamboulas C., Bui N.H.B., Meens J., Dmytryshyn J., Ho V.W., Tang K.H., Paterson J., Clarke B.A., Bernardini M.Q., Bader G.D., Neel B.G., Ailles L.E. Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21 // J Exp Med. – 2020. – Vol. 3, №217(8). – P. 234-243. https://doi.org/10.1084/jem.20191094
44. Kessel K., Seifert R., Weckesser M., Boegemann M., Huss S., Kratochwil C., Haberkorn U., Giesel F., Rahbar K. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging // Ann Nucl Med. – 2022. – Vol. 36, №3. – P. 293-301. https://doi.org/10.1007/s12149-021-01702-8
45. Koerber S.A., Finck R., Dendl K., Uhl M., Lindner T., Kratochwil C., Röhrich M., Rathke H., Ungerechts G., Adeberg S., Herfarth K., Jaeger D., Debus J., Haberkorn U., Giesel F.L. Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT // Eur J Nucl Med Mol Imaging. – 2021. – Vol. 48, №12. – P. 3918-3924. https://doi.org/10.1007/s00259-021-05374-4
46. Kessler L., Ferdinandus J., Hirmas N., Bauer S., Dirksen U., Zarrad F., Nader M., Chodyla M., Milosevic A., Umutlu L., Schuler M., Podleska L.E., Schildhaus H.U., Fendler W.P., Hamacher R. 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial // J Nucl Med. – 2022. – Vol. 63, №1. – P. 89-95. https://doi.org/10.2967/jnumed.121.262096
47. Jin X., Wei M., Wang S., Wang G., Lai Y., Shi Y., Zhang Y., Yang Z., Wang X. Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT // J Nucl Med. – 2022. – Vol. 63, №2. – P. 212-217. https://doi.org/10.2967/jnumed.121.262134
48. Schmidkonz C., Rauber S., Atzinger A., Agarwal R., Götz T.I., Soare A., Cordes M., Prante O., Bergmann C., Kleyer A., Ritt P., Maschauer S., Hennig P., Toms J., Köhner M., Manger B., Stone J.H., Haberkorn U., Baeuerle T., Distler J.H.W., Agaimy A., Kuwert T., Schett G., Ramming A. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging // Ann Rheum Dis. – 2020. – Vol. 79, №11. – P. 1485-1491. https://doi.org/10.1136/annrheumdis-2020-217408